Spring BioScience Corporation
Pleasanton, CA, US· latest recorded location
Spring BioScience Corporation is named on 6 US grants and 15 published applications in this corpus. Its most frequent classification is C07K (Peptides).
- Granted patents
- 6
- Published applications
- 15
- Inventors
- 14
- Granted in 2026 so far
- 0
- Most recent grant
- 23 Jun 2020
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 2 |
| 2005 | 0 | 0 |
| 2006 | 1 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 0 | 2 |
| 2018 | 1 | 6 |
| 2019 | 2 | 1 |
| 2020 | 1 | 2 |
By publication year.
Technology areas
Share of 21 documents
- C07KPeptides21
- G01NInvestigating or analysing materials by determining their chemical or physical properties21
- A61PTherapeutic uses of medicines7
- A61KMedicines and medical preparations5
- A61NElectrotherapy4
- Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests4
- C12NMicroorganisms or enzymes3
- C12YEnzymes3
- A01BSoil working in agriculture or forestry1
Recent patents
- Anti-PD-L1 antibodies and diagnostic uses thereof23 Jun 2020US 10,689,445 B2
- Anti-B7-H3 antibodies and diagnostic uses thereof10 Dec 2019US 10,501,544 B2
- Anti-indoleamine 2,3-dioxygenase 1 antibodies and diagnostic uses thereof8 Oct 2019US 10,436,785 B2
- PD-L1 antibodies and uses thereof6 Feb 2018US 9,885,721 B2
- High affinity monoclonal antibody for recognizing the progesterone receptor (PR) and method for creating the antibody4 Aug 2009US 7,569,675 B2
- Anti-pd-l1 antibodies and diagnostic uses thereof27 Aug 2020US 2020/0270348 A1
- Anti-b7-h3 antibodies and diagnostic uses thereof13 Feb 2020US 2020/0048353 A1
- Anti- indoleamine 2,3-dioxygenase 1 antibodies and diagnostic uses thereof12 Dec 2019US 2019/0376973 A1
- Anti-gpnmb antibodies and diagnostic uses thereof26 Jul 2018US 2018/0208655 A1
- Anti-ox40 antibodies and diagnostic uses thereof26 Jul 2018US 2018/0208666 A1
Most cited
By later US patents
- PD-L1 antibodies and uses thereof5US 9,885,721 B22018
- Anti-PD-L1 antibodies and diagnostic uses thereof4US 10,689,445 B22020
- Anti-B7-H3 antibodies and diagnostic uses thereof1US 10,501,544 B22019
- High affinity monoclonal antibody for recognizing the estrogen receptor (ER) and method for creating the antibody1US 7,148,332 B22006
- High affinity monoclonal antibody for recognizing the progesterone receptor (PR) and method for creating the antibody1US 7,569,675 B22009